Cancer Chemotherapy and Pharmacology

, Volume 61, Issue 5, pp 727–737

Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells

  • Markus Duechler
  • Małgorzata Stańczyk
  • Małgorzata Czyż
  • Maciej Stępnik
Original Article



To possibly increase the in vitro cytotoxic activity of arsenic trioxide (ATO) by combining it with Parthenolide (PRT), a known NF-κB inhibitor and buthionine sulfoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase.


Several cell lines representing various hematological malignancies were treated in vitro with the study drugs alone or in combinations. Flow cytometry was used to assess cell death rates and reative oxygen species production. Glutathione and ATP levels were determinded using a photometric and a luminometric assay, respectively. Cell death was characterised by fluorescence microscopy and DNA fragmentation analysis.


PRT increased cytotoxicity of ATO in seven out of eight cell lines. Addition of buthionine sulfoximine (BSO) further potentiated cytotoxicity of the combined treatment. When combined with PRT and BSO, clinically achievable concentrations of ATO (2.5 μM) induced cytotoxicity rates of 80–98% after 24 h. Importantly, lymphocytes from healthy donors were largely unaffected by these treatment modalities, also after growth stimulation in cell culture. N-acetylcysteine inhibited the cytotoxic effects of the triple combination. Treatment of leukemic cells with ATO, PRT and BSO rapidly depleted cells from glutathione, induced oxidative stress and decreased intracellular ATP levels. Cell death showed characteristics of necrosis presumably as a result of ATP loss.


Based on the observed selectivity towards malignant cells this combination may offer a therapeutic option applicable to different kinds of leukemia.


Arsenic trioxide Parthenolide Buthionine sulfoximine Leukemia therapy Necrosis 


  1. 1.
    Aggarwal BB (2004) Nuclear factor-kappaB, the enemy within. Cancer Cell 6:203–208PubMedCrossRefGoogle Scholar
  2. 2.
    Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV (2004) Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 101:4578–4583PubMedCrossRefGoogle Scholar
  3. 3.
    D’Alessio M, Cerella C, De Nicola M, Bergamaschi A, Magrini A, Gualandi G, Alfonsi AM, Ghibelli L (2003) Apoptotic GSH extrusion is associated with free radical generation. Ann NY Acad Sci 1010:449–452PubMedCrossRefGoogle Scholar
  4. 4.
    Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268–277PubMedGoogle Scholar
  5. 5.
    Davison K, Côté S, Mader S, Miller WH (2003) Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17:931–940PubMedCrossRefGoogle Scholar
  6. 6.
    Eguchi Y, Srinivasan A, Tomaselli KJ, Shimizu S, Tsujimoto Y (1999) ATP-dependent steps in apoptotic signal transduction. Cancer Res 59:2174–2181PubMedGoogle Scholar
  7. 7.
    Felix K, Manna SK, Wise K, Barr J, Ramesh GT (2005) Low level of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Tox 19:67–77CrossRefGoogle Scholar
  8. 8.
    Filomeni G, Aquilano K, Rotilio G, Ciriolo MR (2005) Antiapoptotic response to induced GSH depletion: involvement of heat shock proteins and NF-kappaB activation. Antioxid Redox Signal 7:446–455PubMedCrossRefGoogle Scholar
  9. 9.
    Ghibelli L, Coppola S, Rotilio G, Lafavia E, Maresca V, Ciriolo MR (1995) Non-oxidative loss of glutathione in apoptosis via GSH extrusion. Biochem Biophys Res Commun 216:313–320PubMedCrossRefGoogle Scholar
  10. 10.
    Gong J, Traganos F, Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218:314–319PubMedCrossRefGoogle Scholar
  11. 11.
    Gupta S, Yel L, Kim D, Kim C, Chiplunkar S, Gollapudi S (2003) Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther 2:711–719PubMedGoogle Scholar
  12. 12.
    Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S (2005) Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 94:695–707PubMedCrossRefGoogle Scholar
  13. 13.
    Hu XM, Hirano T, Oka K (2003) Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother Pharmacol 52:47–58PubMedCrossRefGoogle Scholar
  14. 14.
    Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102–2111PubMedGoogle Scholar
  15. 15.
    Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275:36062–36066PubMedCrossRefGoogle Scholar
  16. 16.
    Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431–436PubMedCrossRefGoogle Scholar
  17. 17.
    Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ (2005) NF-kB and FLIP in arsenic trioxide (ATO)–induced apoptosis in myelodysplastic syndromes (MDSs). Blood 106:3917–3925PubMedCrossRefGoogle Scholar
  18. 18.
    Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM (2001) The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8:759–766PubMedCrossRefGoogle Scholar
  19. 19.
    Lemarie A, Morzadec C, Merino D, Micheau O, Fardel O, Vernhet L (2006) Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. J Pharmacol Exp Ther 316:304–314PubMedCrossRefGoogle Scholar
  20. 20.
    Li M, Cai JF, Chiu JF (2002) Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem 87:29–38PubMedCrossRefGoogle Scholar
  21. 21.
    Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A (2004) Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Diff 11:737–746CrossRefGoogle Scholar
  22. 22.
    Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B (2003) Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 102:1028–1034PubMedCrossRefGoogle Scholar
  23. 23.
    Nakshatri H, Rice SE, Bhat-Nakshatri P (2004) Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23:7330–7344PubMedCrossRefGoogle Scholar
  24. 24.
    Pelicano H, Martin DS, Xu R-H, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633–4646PubMedCrossRefGoogle Scholar
  25. 25.
    Saito Y, Nishio K, Ogawa Y, Kimata J, Kinumi T, Yoshida Y, Noguchi N, Niki E (2006) Turning point in apoptosis/necrosis induced by hydrogen peroxide. Free Radic Res 40:619–630PubMedCrossRefGoogle Scholar
  26. 26.
    Samikkannu T, Chen CH, Yih LH, Wang AS, Lin SY, Chen TC, Jan KY (2003) Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity. Chem Res Toxicol 16:409–414PubMedCrossRefGoogle Scholar
  27. 27.
    Seo T, Urasaki Y, Takemura H, Ueda T (2005) Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines. Anticancer Res 25:991–998PubMedGoogle Scholar
  28. 28.
    Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354–3360PubMedGoogle Scholar
  29. 29.
    Steele AJ, Jones DT, Ganeshaguru K, Duke VM, Yogashangary BC, North JM, Lowdell MW, Kottaridis PD, Mehta AB, Prentice AG, Hoffbrand AV, Wickremasinghe RG (2006) The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 20:1073–1079PubMedCrossRefGoogle Scholar
  30. 30.
    Sukhanov S, Higashi Y, Shai SY, Itabe H, Ono K, Parthasarathy S, Delafontaine P (2006) Novel effect of oxidized low-density lipoprotein. Cellular ATP depletion via downregulation of Glyceraldehyde-3-Phosphate dehydrogenase. Circ Res 99:191–200PubMedCrossRefGoogle Scholar
  31. 31.
    Tabellini G, Cappellini A, Tazzari PL, Fala F, Billi AM, Manzoli L, Cocco L, Martelli AM (2005) Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 202:623–634PubMedCrossRefGoogle Scholar
  32. 32.
    Troyano A, Sancho P, Fernandez C, de Blas E, Bernardi P, Aller P (2003) The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death Diff 10:889–898CrossRefGoogle Scholar
  33. 33.
    Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S (2004) NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 18:11–17PubMedCrossRefGoogle Scholar
  34. 34.
    Verstovsek S, Giles F, Quinta’s-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H (2006) Arsenic derivatives in hematologic malignancies, a role beyond acute promyelocytic leukemia? Hematol Oncol 24:181–188PubMedCrossRefGoogle Scholar
  35. 35.
    Wang W, Adachi M, Kawamura R, Sakamoto H, Hayashi T, Ishida T, Imai K, Shinomura Y (2006) Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 11:2225–2235PubMedCrossRefGoogle Scholar
  36. 36.
    Woo SH, Park IC, Park MJ, An S, Lee HC, Jin HO, Park SA, Cho H, Lee SJ, Gwak HS, Hong YJ, Hong SI, Rhee CH (2004) Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int J Cancer 112:596–606PubMedCrossRefGoogle Scholar
  37. 37.
    Yang CH, Kuo ML, Chen JC, Chen YC (1999) Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81:796–799PubMedCrossRefGoogle Scholar
  38. 38.
    Yi J, Gao F, Shi G, Li H, Wang Z, Shi X, Tang X (2002) The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 7:209–215PubMedCrossRefGoogle Scholar
  39. 39.
    Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM (2004) Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis 25:2191–2199PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang S, Ong CN, Shen HM (2004) Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 208:143–153PubMedCrossRefGoogle Scholar
  41. 41.
    Zhou L, Jing Y, Styblo M, Chen Z, Waxman S (2005) Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 105:1198–1203PubMedCrossRefGoogle Scholar
  42. 42.
    Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91: 772–778PubMedCrossRefGoogle Scholar
  43. 43.
    Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance, immunoselection and immunosubversion. Nat Rev Immunol 6:715–727PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Markus Duechler
    • 1
  • Małgorzata Stańczyk
    • 1
  • Małgorzata Czyż
    • 2
  • Maciej Stępnik
    • 1
  1. 1.Department of Toxicology and CarcinogenesisNofer Institute of Occupational MedicineŁódźPoland
  2. 2.Department of Molecular Biology of CancerMedical University of ŁódźŁódźPoland

Personalised recommendations